Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

99.18 -0.68 (-0.68%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Merck & Co

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
95 96 Next >
Forget Shopify: This Stock Has Made Far More Millionaires
It's a reliable winner with plenty more room to run. 
Via The Motley Fool
Russell 2000 Index Best And Worst Performing Stocks Of 2024
The Russell 2000 index continued to underperform the Dow Jones and Nasdaq 100 indices in the first quarter of 2024. 
Via Talk Markets
Topics Stocks
Exposures US Equities
Expert Ratings For Merck & Co
Via Benzinga
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
From Merck & Co., Inc.
Via Business Wire
Looking At Merck & Co's Recent Unusual Options Activity
Via Benzinga
Smart Money Is Betting Big In MRK Options
Via Benzinga
Looking At Merck & Co's Recent Unusual Options Activity
Via Benzinga
Which Blue Chip Led The Dow Jones Industrials In Q1?
Disney and Caterpillar led gains among Dow Jones stocks in the first quarter. Boeing posted the largest decline. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
3 Strong Buy Healthcare Stocks to Add to Your Q2 Must-Watch List
In an aging world, strong buy healthcare stocks like UNH, ABT, and MRK shine with dividends, innovation, and market growth. 
Via InvestorPlace
Stock Market Rally Shows Breadth As Leaders Take A Breath: Weekly Review
The stock market rally showed breadth, with small caps leading the way to a 24-month high. Growth leaders like Nvidia took a break. 
Via Investor's Business Daily
Japan Index Falls While Asia And Europe Markets Rise, And Gold Exceeds $2,220 - Global Markets Today While US Slept
Via Benzinga
European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for Resectable Non-Small Cell Lung Cancer (NSCLC) at High Risk of Recurrence in Adults
From Merck & Co., Inc.
Via Business Wire
The Reserve Bank Of South Africa Kept The Rate At 8.25%
The Reserve Bank of South Africa unanimously decided to keep the key repo rate at 8.25%, marking the fifth consecutive meeting at 2009 levels, as expected. 
Via Talk Markets
Merck Stock Soars On FDA Approval for Winrevair: Technical Analysis And Market Outlook
Merck acquired sotatercept via its $11 billion acquisition of Acceleron Pharma, underscoring a commitment to advancing innovative therapies. 
Via Benzinga
Exposures Product Safety
The Most Important Catalyst For Merck's Stock In 2024 Could Be Sotatercept Launch, Analyst Says
Cantor Fitzgerald notes Merck's robust stock performance, up 15% YTD vs S&P 500's 10%.Potential peak sales projections ranging from $1 billion to $8 billion. Merck targets 40,000 potential patients. 
Via Benzinga
Topics Stocks
Exposures US Equities
Cintas Reports Upbeat Earnings, Joins PaySign, Noah Holdings And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Merck's $11B Bet Pays As FDA Approves Sotatercept For Rare Lung Disease
FDA approves Merck's Winrevair for PAH treatment. First-in-class therapy to enhance exercise capacity, improve WHO FC, and reduce clinical worsening. Available in select U.S. pharmacies by April.... 
Via Benzinga
Exposures Product Safety
US Stocks Set For Rebound, Aim To Snap 3-Session Slump And Close Quarter Strong: Analyst Foresees Robust April Ahead
Bargain hunters may flock to the market on Wednesday following three consecutive sessions of losses. 
Via Benzinga
FDA Approves Merck’s WINREVAIR™ (sotatercept-csrk), a First-in-Class Treatment for Adults with Pulmonary Arterial Hypertension (PAH, WHO* Group 1)
From Merck & Co., Inc.
Via Business Wire
Merck's Cardiovascular 'Renaissance' Is Here With The First Approval Of A $10 Billion Franchise
The FDA signed off on Winrevair, a treatment for pulmonary arterial hypertension. 
Via Investor's Business Daily
Exposures Product Safety
Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment
Stifel covers Summit Therapeutics, highlighting ivonescimab's promise in phase 3 lung cancer trials, potential market expansion worth billions, and a buy rating with $8 target. Updates from Akeso in... 
Via Benzinga
Nvidia's AI Tech Part of Novo Nordisk's New Supercomputer
Novo Nordisk and Nvidia have teamed up to develop supercomputers, aiming to accelerate drug discovery development using advanced AI technologies. 
Via MarketBeat
Topics Artificial Intelligence
Exposures Artificial Intelligence
Week In Review: Three Multinationals Plan Investments In Southeast Asia Facilities
Shanghai WuXi Biologics has broken ground on a $1.4 billion facility in Singapore. Meanwhile, Novo Nordisk announced plans to invest $556 million to expand its Tianjin city production facility. 
Via Talk Markets
After Failed Prostate Cancer Study Merck's Keytruda Combination Therapy Flunks In Late-Stage Lung Cancer Study
Merck's latest findings from the KEYLYNK-006 trial on Keytruda and Lynparza combination therapy for metastatic non-small cell lung cancer reveal outcomes on survival and progression. 
Via Benzinga
Bull Market and Beyond: 2 Stocks to Buy and Hold Forever
These stocks have been providing excellent returns for a long time. 
Via The Motley Fool
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
From Merck & Co., Inc.
Via Business Wire
NYSE:MRK is probably undervalued for the fundamentals it is displaying.
Don't overlook MERCK & CO. INC. (NYSE:MRK)—it's a hidden gem with strong fundamentals and an attractive price tag. 
Via Chartmill
Geron Stock Doubles After Imetelstat Receives FDA Panel Approval
Geron stock is up more than 92% after the company's flagship blood cancer therapy received approval from an FDA advisory panel 
Via MarketBeat
Exposures Product Safety
Merck Highlights Data From Multiple Phase 3 Trials For Its Investigational Pneumococcal Conjugate Vaccine
Merck's Phase 3 data on V116, a 21-valent pneumococcal conjugate vaccine for adults, show promising immunogenicity across diverse populations, including those at risk. 
Via Benzinga
Merck Announces Positive Data on V116, an Investigational, 21-Valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Demonstrated Immune Responses in Adults
From Merck & Co., Inc.
Via Business Wire
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
95 96 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS